Buy Mounjaro Lilly name brand Tirzepatide 5 mg single dose vial. 1 Week Supply

ORDER NOTE: We can only ship a maximum of 4 units of Mounjaro 5 mg per order.

Mounjaro 2.5 mg: Comprehensive Guide

Mounjaro (tirzepatide) 2.5 mg is a once-weekly injectable treatment developed by Eli Lilly to assist adults in managing type 2 diabetes and, in some instances, promoting weight loss. As a dual GIP and GLP-1 receptor agonist, Mounjaro uniquely targets two hormones—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—to regulate blood sugar and appetite. This innovative mechanism makes it a powerful option for glycemic control and weight management, though its use for weight loss may be off-label unless prescribed as Zepbound, its weight-loss-specific counterpart.

Application for Type 2 Diabetes

Mounjaro 2.5 mg is FDA-approved for adults with type 2 diabetes to enhance blood glucose levels when combined with a healthy diet and regular exercise. It stimulates insulin release when blood sugar is high, decreases liver glucose production, and slows digestion to prevent sharp glucose spikes. In clinical trials, 75% to 90% of patients across various doses, including 2.5 mg, achieved an A1C below 7%, with baseline A1Cs of 7.9% to 8.6% over 40 to 52 weeks. The 2.5 mg dose is the starting dose, administered for the first 4 weeks to allow the body to adjust, after which patients may step up to 5 mg or higher (up to 15 mg) if needed for better control. Mounjaro is not indicated for type 1 diabetes, children under 18, or those with a history of pancreatitis, as its safety in such cases is not established.

Role in Weight Loss

Although Mounjaro 2.5 mg is not specifically approved for weight loss, it is frequently prescribed off-label for this purpose due to its notable weight-reduction effects. Tirzepatide, the active ingredient, is also approved for weight loss under the brand Zepbound. Mounjaro curbs appetite, enhances satiety, and delays gastric emptying, leading to lower calorie consumption. In trials like SURMOUNT-1, patients without diabetes lost up to 22.5% of their body weight (about 52 pounds) on higher doses over 72 weeks. For those with type 2 diabetes (SURMOUNT-2), weight loss ranged from 13.4% to 15.7% (29.8 to 34.4 pounds) on 10 mg and 15 mg doses. At 2.5 mg, weight loss is typically less pronounced, averaging around 5 to 10 pounds, but still significant. Patients should complement Mounjaro with a balanced, low-calorie diet and active lifestyle for optimal results.

Precautions and Contraindications

Mounjaro 2.5 mg carries a boxed warning for the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Animal studies linked tirzepatide to thyroid tumors, though human risk remains uncertain. Avoid Mounjaro if you or a family member have a history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Seek medical attention if you notice symptoms like a neck mass, persistent hoarseness, or difficulty swallowing.

Additional risks include pancreatitis (severe stomach pain, possibly with vomiting), hypoglycemia (especially with insulin or sulfonylureas), kidney issues (from dehydration due to nausea or diarrhea), and gallbladder problems (e.g., gallstones, indicated by upper abdominal pain or yellowing skin). Mounjaro may cause intense digestive side effects, temporary vision changes, or rare mood shifts like anxiety or depression. It’s not advised for those with severe gastrointestinal conditions, such as gastroparesis, or a history of severe allergic reactions to tirzepatide.

Consult your healthcare provider to confirm Mounjaro 2.5 mg is appropriate for you, and adhere to their dosing recommendations.

Mounjaro (Zepbound) Tirzepatide 2.5 mg

Brand Lilly
Product Code: Mounjaro - Tirzepatide 2.5 mg Vial
Availability: In Stock

$140.00
Ex Tax: $140.00

Min Quantity	Product Price after min quantity	Amount Saving percentage	Amount Saving price
1	$140.00	0.00 %	$0.00
3	$120.00	14.29 %	$20.00

Qty

0 reviews / Write a review